## 3 Results
### Hemodynamic Results of CTEPH According to Subleural Perfusion on DE-CT  
The baseline clinical characteristics and hemodynamics of patients with CTEPH in the normally perfused and poorly perfused groups are summarized in Table 2. Patient characteristics, including age, sex ratio, and functional status, were similar between the groups. Patients in the poorly perfused group had worse hemodynamics with higher PVR (768 \(\pm\) 445 dynes-sec/cm\({}^{5}\) vs. 463 \(\pm\) 284 dynes-sec/cm\({}^{5}\), \(p\) < 0.01) and lower SvO\({}_{2}\) (60.3 \(\pm\) 8.2% vs. 64.9 \(\pm\) 7.4%, \(p\) < 0.01), and they also had a lower diffusing capacity for carbon monoxide divided by alveolar volume (DLCO/VA) (60.4 \(\pm\) 16.8% vs. 75.9 \(\pm\) 15.7%, \(p\) < 0.01). Of the 58 patients, 27 (47%) in the poorly perfused group and 26 of the 55 patients (47%) in the normally perfused group were treated with a soluble guanylate cyclase stimulator (riociquat, an approved drug for CTEPH). Table 3 summarizes the hemodynamic results of patients in both groups who received adequate BPA and underwent re-evaluation using RHC (\(n\) = 86). Hemodynamic parameters improved to nearly normal in both groups (PVR: 611 \(\pm\) 467 dynes-sec/cm\({}^{5}\) to 270 \(\pm\) 118 dynes-sec/cm\({}^{5}\), \(p\) < 0.001, mean pulmonary arterial pressure (PAP): 37.5 \(\pm\) 10.5 mmHg to 19.6 \(\pm\) 5.0 mmHg, \(p\) < 0.001 in the poorly perfused group; PVR: 422 \(\pm\) 280 dynes-sec/cm\({}^{5}\) \begin{table}
\begin{tabular}{l c c c} \hline \hline \multicolumn{1}{c}{**Variable**} & \multicolumn{1}{c}{**Poorly Perfused**} & \multicolumn{1}{c}{**Normally Perfused**} & \\  & \multicolumn{1}{c}{_n_ = 58} & \multicolumn{1}{c}{_n_ = 55} & \multicolumn{1}{c}{_p_ **Value**} \\ \hline \multicolumn{5}{l}{_Baseline characteristics_} \\ \multicolumn{5}{l}{Age (years)} \\ \multicolumn{5}{l}{Male (\(n\), \%)} \\ \multicolumn{5}{l}{NYHA FC (I/II/III/IV) (\%)} \\ \multicolumn{5}{l}{_Baseline hemodynamics_} \\ \multicolumn{5}{l}{Mean RAP (mmHg)} \\ \multicolumn{5}{l}{Systolic PAP (mmHg)} \\ \multicolumn{5}{l}{Diastolic PAP (mmHg)} \\ \multicolumn{5}{l}{Mean PAP (mmHg)} \\ \multicolumn{5}{l}{PAWP (mmHg)} \\ \multicolumn{5}{l}{CARLAOTE output (L/min)} \\ \multicolumn{5}{l}{CARLAOTE output (L/min)} \\ \multicolumn{5}{l}{CARLAOTE index (L/min/m\({}^{2}\))} \\ \multicolumn{5}{l}{CARLAOTE index (L/min/m\({}^{2}\))} \\ \multicolumn{5}{l}{VARLAOTE index (L/min/m\({}^{2}\))} \\ \multicolumn{5}{l}{PVR (dynes-sec/cm\({}^{5}\))} \\ \multicolumn{5}{l}{SVO\({}_{2}\) (\%)} \\ \multicolumn{5}{l}{_Exercise capacity_} \\ \multicolumn{5}{l}{6 MWD (m)} \\ \multicolumn{5}{l}{Peak VO\({}_{2}\) in CPET (mL/min/kg)} \\ \multicolumn{5}{l}{VEV/VCO\({}_{2}\) slope in CPET} \\ \multicolumn{5}{l}{_Lung function test_} \\ \multicolumn{5}{l}{\%VC (\%)} \\ \multicolumn{5}{l}{FEV 1.0\% (\%)} \\ \multicolumn{5}{l}{\%DLCO/VA (\%)} \\ \multicolumn{5}{l}{_Medications initiated since diagnosis_} \\ \multicolumn{5}{l}{_anticagulation_} \\ \multicolumn{5}{l}{Warfarin (\(n\), \%)} \\ \multicolumn{5}{l}{DOAC (\(n\), \%)} \\ \multicolumn{5}{l}{_PAH-specific drugs_} \\ \multicolumn{5}{l}{ERA (\(n\), \%)} \\ \multicolumn{5}{l}{PDE5-i (\(n\), \%)} \\ \multicolumn{5}{l}{sGC stimulator (\(n\), \%)} \\ \multicolumn{5}{l}{_List of abbreviations_: NYHA FC: New York Heart Association functional class; BNP: brain natriuretic peptide; PRW: pulmonary blood volume; RAP: right atrial pressure; PAP: pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; gMWD: 6 min walk distance; VO\({}_{2}\): oxygen consumption; CPET: cardio-pulmonary exercise test; VE/VCO\({}_{2}\): ventilatory equivalent for carbon dioxide; VC: vital capacity; FEV: forced vital capacity; DLCO/VA: diffusing capacity for carbon monoxide divided by the alveolar volume; DOAC: direct oral anticoagulants; ERA: endothelin–receptor antagonists; PDES-i: phosphodiesterase three-5 inhibitors; sGC: soluble guanylate cyclase; Data are given as mean \(\pm\) standard deviation. \\ \hline \hline \end{tabular}
\end{table}